Xenetic Biosciences, Inc. (XBIO)
$2.10-0.94%Close
SELLCRISIS · day 20
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4M
- Beta
- 2.20
- P/E (TTM)
- -1.76
- Short % float
- 0.71%
- Days to cover
- 1.0
- SI change
- -42.7%
- 1W
- -0.94%
- 1M
- -51.50%
- vs SPY 1W
- -0.80%
- vs SPY 1M
- -54.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 14
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-24.4%
REV YoY-
ROE-40.6%
EPS YoY-
ROA-35.5%
GROSS100
OP-81
NET-76
[VALUATION]
P/E TTM-1.76
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.79
P/FCF-
EV/EBITDA0.67
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.43
ND/EBITDA-
BETA2.20
Company news
FAQ
- What is LOPJLB’s current signal on XBIO?
- LOPJLB’s latest quantitative signal on Xenetic Biosciences, Inc. (XBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is XBIO in?
- Xenetic Biosciences, Inc. (XBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Xenetic Biosciences, Inc. (XBIO) do?
- Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, …